Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to include the treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).
